Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's Tax Provisions fell 34580.5% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year increase of 19194.03%. This contributed to the annual value of $19.4 million for FY2024, which is 22709.32% up from last year.
  • Latest data reveals that Theravance Biopharma reported Tax Provisions of -$6.5 million as of Q3 2025, which was down 34580.5% from $18.4 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Tax Provisions registered a high of $18.4 million during Q2 2025, and its lowest value of -$6.5 million during Q3 2025.
  • For the 5-year period, Theravance Biopharma's Tax Provisions averaged around $1.9 million, with its median value being $227000.0 (2021).
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 714285.71% in 2022, then skyrocketed by 2926000.0% in 2023.
  • Over the past 5 years, Theravance Biopharma's Tax Provisions (Quarter) stood at -$200000.0 in 2021, then skyrocketed by 89.5% to -$21000.0 in 2022, then soared by 16738.1% to $3.5 million in 2023, then soared by 305.29% to $14.2 million in 2024, then crashed by 145.93% to -$6.5 million in 2025.
  • Its last three reported values are -$6.5 million in Q3 2025, $18.4 million for Q2 2025, and -$600000.0 during Q1 2025.